Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds

Cancer Letters

Volumn 293, Issue 1, 2010, Pages 73-81

  Joanitti, Graziella Anselmo ^a   Azevedo, Ricardo Bentes ^a   Freitas, Sonia Maria ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Apoptosis; Bowman Birk; Breast cancer; Lysosome membrane permeabilization; Protease inhibitor

Indexed keywords

BOWMAN BIRK INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COWPEA; CYTOSTASIS; CYTOTOXICITY TEST; DNA FRAGMENTATION; HUMAN; HUMAN CELL; LYSOSOME MEMBRANE; MEMBRANE PERMEABILITY; PLANT SEED; PRIORITY JOURNAL;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; FABACEAE; FEMALE; HUMANS; LYSOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, FLUORESCENCE; PLANT PROTEINS; SEEDS; TRYPSIN INHIBITORS;

PISUM SATIVUM; VIGNA UNGUICULATA;

EID: 77952425329     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.12.017     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Moulder S., Hortobagyi G.N. Advances in the treatment of breast cancer. Clin. Pharmacol. Ther. 2008, 83:26-36.
3. Joanitti G.A., Freitas S.M., Silva L.P. Proteinaceous protease inhibitors: structural features and multiple functional faces. Curr. Enzyme Inhib. 2006, 2:199-217.
4. Kennedy A.R. Chemopreventive agents: protease inhibitors. Pharmacol. Ther. 1998, 78:167-209.
5. Kennedy A.R., Wan X.S. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 2002, 50:125-133.
6. Chen Y.W., Huang S.C., Lin-Shiau S.Y., Lin J.K. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26:1296-1306.
7. Saito T., Sato H., Virgona N., Hagiwara H., Kashiwagi K., Suzuki K., Asano R., Yano T. Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43. Cancer Lett. 2007, 253:249-257.
8. Billings P.C., St.Clair W.H., Maki P.A., Kennedy A.R. Distribution of the Bowman-Birk protease inhibitor in mice following oral administration. Cancer Lett. 1992, 62:191-197.
9. Dittmann K.H., Mayer C., Rodemann H.P. Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman-Birk protease inhibitor. Curr. Med. Chem. Anticancer Agents 2003, 3:360-363.
10. Armstong W.B., Kennedy A.R., Wan X.S., Taylor T.H., Nguyen Q.A., Jensen J., Thompson W., Largerberg W., Meyskens F.L. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin. Cancer Res. 2000, 6:4684-4691.
11. Entrez PubMed Database [Database on the Internet]. Bethesda (MD): National Center for Biotechnology Information (NCBI). The Following Words were Used in the Search Bar: Bowman and Birk and Cancer. Review Articles, Comments and Not Related Reports were Excluded from the Count. (Files Updated Weekly; Cited 2009 December 22th). http://www.ncbi.nlm.nih.gov/sites/entrez.
12. Ventura M.M., Xavier-Filho J. A trypsin and chymotrypsin inhibitor from black-eyed pea (Vigna sinensis). I. Purification and partial characterization. Ann. Acad. Bras. Cienc. 1966, 38:553-566.
13. Fachetti H.C.S., Mizuta K., Ventura M.M. Thermodynamics of the black-eyed pea trypsin and chymotrypsin inhibitor. Ann. Acad. Bras. Cienc. 1984, 56:311-317.
14. Freitas S.M., de Mello L.V., Da Silva M.C., Vriend G., Neshich G., Ventura M.M. Analysis of the black-eyed pea trypsin and chymotrypsin inhibitor-a-chymotrypsin complex. FEBS Lett. 1997, 409:121-127.
15. Freitas S.M., Ikemoto H., Ventura M.M. Thermodynamics of the binding of chymotrypsin with the black-eyed pea trypsin and chymotrypsin inhibitor (BTCI). J. Protein Chem. 1999, 18:307-313.
16. Silva L.P., Leite J.R.S.A., Bloch C., Freitas S.M. Thermal stability of a black eyed pea trypsin/chymotrypsin inhibitor (BTCI). Protein Pept. Lett. 2001, 7:397-401.
17. Silva L.P., Azevedo R.B., Morais P.C., Ventura M.M., Freitas S.M. Oligomerization states of Bowman-Birk inhibitor by atomic force microscopy and computational approaches. Proteins 2005, 61:642-648.
18. Barbosa J.A., Silva L.P., Teles R.C., Esteves G.F., Azevedo R.B., Ventura M.M., Freitas S.M. Crystal structure of the Bowman-Birk inhibitor from Vigna unguiculata seeds in complex with β-trypsin at 1.55 a resolution and its structural properties in association with proteinases. Biophys. J. 2007, 92:1638-1650.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
20. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr. Issues Mol. Biol. 2001, 3:67-70.
21. Glauert A.M., Lewis P.R. Biological Specimen Preparation for Transmission Electron Microscopy 1998, Princeton University Press, Cambridge. first ed.
22. Clemente A., Gee J.M., Johnson I.T., Mackenzie D.A., Domoney C. Pea (Pisum sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J. Agric. Food Chem. 2005, 53:8979-8986.
23. Wan X.S., Hamilton T.C., Ware J.H., Donahue J.J., Kennedy A.R. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. Nutr. Cancer 1998, 31:8-17.
24. Zhang L., Wan X.S., Donahue J.J., Ware J.H., Kennedy A.R. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells. Nutr. Cancer 1999, 33:165-173.
25. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
26. Kroemer G., Jäättelä M. Lysosomes and autophagy in cell death control. Nature 2005, 5:886-897.
27. Kirkegaard T., Jäättelä M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 2009, 1793:746-754.
28. Groth-Pedersen L., Ostenfeld M.S., Høyer-Hansen M., Nylandsted J., Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007, 67:2217-2225.